+

WO1991019707A3 - 1-benzopyran-4-ones et 2-amino-1,3-benzoxazine-4-ones antiathero sclerotiques et antithrombotiques - Google Patents

1-benzopyran-4-ones et 2-amino-1,3-benzoxazine-4-ones antiathero sclerotiques et antithrombotiques Download PDF

Info

Publication number
WO1991019707A3
WO1991019707A3 PCT/US1991/004140 US9104140W WO9119707A3 WO 1991019707 A3 WO1991019707 A3 WO 1991019707A3 US 9104140 W US9104140 W US 9104140W WO 9119707 A3 WO9119707 A3 WO 9119707A3
Authority
WO
WIPO (PCT)
Prior art keywords
ones
antiatherosclerotic
benzoxazine
benzopyran
antithrombotic
Prior art date
Application number
PCT/US1991/004140
Other languages
English (en)
Other versions
WO1991019707A2 (fr
Inventor
Ronald B Gammill
Thomas M Judge
Joel Morris
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Priority to DE69127690T priority Critical patent/DE69127690T2/de
Priority to EP91911326A priority patent/EP0525123B1/fr
Publication of WO1991019707A2 publication Critical patent/WO1991019707A2/fr
Publication of WO1991019707A3 publication Critical patent/WO1991019707A3/fr
Priority to GR970403134T priority patent/GR3025485T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des composés de la formule (I), utiles en association avec un support pharmaceutique comme agents antiathérosclérotiques. De plus, divers composés de la formule (I) constituent des inhibiteurs utiles de la prolifération cellulaire.
PCT/US1991/004140 1990-06-20 1991-06-18 1-benzopyran-4-ones et 2-amino-1,3-benzoxazine-4-ones antiathero sclerotiques et antithrombotiques WO1991019707A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE69127690T DE69127690T2 (de) 1990-06-20 1991-06-18 Antiatherosklerotische und antithrombotische 1-benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on-derivate
EP91911326A EP0525123B1 (fr) 1990-06-20 1991-06-18 1-benzopyran-4-ones et 2-amino-1,3-benzoxazine-4-ones antiathero sclerotiques et antithrombotiques
GR970403134T GR3025485T3 (en) 1990-06-20 1997-11-26 Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54112690A 1990-06-20 1990-06-20
US541,126 1990-06-20

Publications (2)

Publication Number Publication Date
WO1991019707A2 WO1991019707A2 (fr) 1991-12-26
WO1991019707A3 true WO1991019707A3 (fr) 1992-03-05

Family

ID=24158277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/004140 WO1991019707A2 (fr) 1990-06-20 1991-06-18 1-benzopyran-4-ones et 2-amino-1,3-benzoxazine-4-ones antiathero sclerotiques et antithrombotiques

Country Status (10)

Country Link
EP (1) EP0525123B1 (fr)
JP (1) JPH05509302A (fr)
AT (1) ATE158288T1 (fr)
AU (1) AU7998291A (fr)
CA (1) CA2081577A1 (fr)
DE (1) DE69127690T2 (fr)
DK (1) DK0525123T3 (fr)
ES (1) ES2106783T3 (fr)
GR (1) GR3025485T3 (fr)
WO (1) WO1991019707A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605896A (en) * 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
US5474994A (en) * 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
IT1254469B (it) * 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
US5358959A (en) * 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds
EP0619314A1 (fr) * 1993-04-09 1994-10-12 Eli Lilly And Company Dérivés de 4-phényl-4H-naphtho 2,1-b pyran et leur utilisation pharmaceutique
US5556871A (en) * 1995-04-24 1996-09-17 President & Fellows Of Harvard College Method for treating epithelial precancerous lesions with topical inidazoles
US6180625B1 (en) 1998-03-24 2001-01-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
DE19850131A1 (de) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
AU3704400A (en) * 1999-03-04 2000-09-21 E.I. Du Pont De Nemours And Company Fused bicyclic oxazinone and thiazinone fungicides
ES2286093T3 (es) 2000-01-24 2007-12-01 Astrazeneca Ab Compuestos terapeuticos morfolino-sustituidos.
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) * 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
RU2308454C9 (ru) 2002-04-17 2008-05-10 Цитокинетикс, Инк. Соединения, композиции на их основе и способы их использования
US6949538B2 (en) 2002-07-17 2005-09-27 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004016607A1 (fr) * 2002-08-16 2004-02-26 Kinacia Pty Ltd. Inhibition de la phosphoinositide 3-kinase beta
CN101260104A (zh) * 2002-08-16 2008-09-10 阿斯利康(瑞典)有限公司 抑制磷酸肌醇3-激酶β
CA2518916A1 (fr) * 2003-04-03 2004-10-21 Joseph R. Garlich Promedicaments d'inhibiteurs de pi-3 kinase
SI1631295T1 (sl) * 2003-06-06 2010-06-30 Arexis Ab Uporaba kondenziranih heterocikličnih spojin kotSCCE inhibitorjev za zdravljenje kožnih bolezni
CN1867566B (zh) 2003-08-13 2010-06-16 库多斯药物有限公司 氨基吡喃酮和它们作为atm抑制剂的用途
EP1794151A1 (fr) 2004-09-20 2007-06-13 Kudos Pharmaceuticals Limited Inhibiteurs d'adn-pk
EP1848712A1 (fr) 2005-02-09 2007-10-31 Kudos Pharmaceuticals Ltd Inhibiteurs d'atm
AR053358A1 (es) 2005-04-15 2007-05-02 Cancer Rec Tech Ltd Inhibidores de adn - pk
JPWO2009038064A1 (ja) * 2007-09-19 2011-01-06 株式会社医薬分子設計研究所 Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体
EP2245030A4 (fr) * 2008-01-25 2012-03-21 Astrazeneca Ab Acide (-)2-[1-(7-méthyl-2-(morpholin-4-yl)-4-oxo-4<i>h</i>-pyrido[1,2-<i>a</i>]pyrimidin-9-yl)éthylamino]benzoïque énantiomériquement pur, son utilisation en thérapie médicale, et composition pharmaceutique le contenant
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
ES2648154T3 (es) * 2012-01-26 2017-12-28 Daiichi Sankyo Company, Limited Derivado de cromona que tiene un efecto promotor de la osteogénesis
US20250136581A1 (en) * 2021-08-12 2025-05-01 Shanghai Simr Biotechnology Co., Ltd. Substituted triazole derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4092416A (en) * 1975-12-09 1978-05-30 Boehringer Mannheim Gmbh Benzopyrone derivatives exhibiting anti-allergic activity
EP0248420A2 (fr) * 1986-06-04 1987-12-09 Daiichi Seiyaku Co., Ltd. Dérivés de benzopyranne
WO1990006921A1 (fr) * 1988-12-21 1990-06-28 The Upjohn Company 1-benzopyran-4-ones-et 2-amino-1,3-benzoxazine-4-ones antiatherosclerotiques et antithrombotiques

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4092416A (en) * 1975-12-09 1978-05-30 Boehringer Mannheim Gmbh Benzopyrone derivatives exhibiting anti-allergic activity
EP0248420A2 (fr) * 1986-06-04 1987-12-09 Daiichi Seiyaku Co., Ltd. Dérivés de benzopyranne
WO1990006921A1 (fr) * 1988-12-21 1990-06-28 The Upjohn Company 1-benzopyran-4-ones-et 2-amino-1,3-benzoxazine-4-ones antiatherosclerotiques et antithrombotiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, volume 87, no. 15, 10 October 1977 (Columbus, Ohio, US) A. Ermili et al.: "Chemical and pharmacological research on pyran derivatives. Note VIII. Synthesis of 2-(dialkylamino)-7-methoxychromones and their derivatives", see page 588, abstract 117750g, & Farmaco, Edizione Scientifica 1977, 32(5), 375-387 (cited in the application) *
European Journal of Medicinal Chemistry, volume 23, no. 3, May-June 1988 (Paris, FR) M. Mazzei et al.: "Synthesis and anti-platelet activity of some 2-(dialkylamino)chromones", pages 237-242, see the whole document (cited in the application) *
Journal of Heterocyclic Chemistry, volume 18, no. 4, June 1981, Hetero Corp. (Provo, US) J.R. Bantick et al.: "Synthesis of 2-aminochromones. Studies on the nucleophilic displacement of sulphinyl and sulphonyl groups in the 2-position of 5,8-dimethoxychromone", pages 678-684, see the whole article (cited in the application) *

Also Published As

Publication number Publication date
ATE158288T1 (de) 1997-10-15
DE69127690T2 (de) 1998-02-12
GR3025485T3 (en) 1998-02-27
DE69127690D1 (de) 1997-10-23
EP0525123B1 (fr) 1997-09-17
ES2106783T3 (es) 1997-11-16
WO1991019707A2 (fr) 1991-12-26
JPH05509302A (ja) 1993-12-22
DK0525123T3 (da) 1998-05-04
AU7998291A (en) 1992-01-07
EP0525123A1 (fr) 1993-02-03
CA2081577A1 (fr) 1991-12-21

Similar Documents

Publication Publication Date Title
AU7998291A (en) Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
GR3023233T3 (en) Inhibitors of dipeptidyl-aminopeptidase type iv
DE58906377D1 (en) Difluormethylverbindungen.
NZ233735A (en) Heterocyclic substituted aminophenol derivatives
BG101112A (en) The use of heterocyclic compounds
CA2396738A1 (fr) Derives du thiazole comme inhibiteur actif du radical superoxyde
MY131595A (en) Heterocyclically substituted phenyl-cyclohexane- carboxylic acid derivatives
MX9604367A (es) Hidroxipiridinonas novedosas.
NZ237884A (en) N-hydroxy-n-linolanyl (chromanyl or quinolinyl) alkyl urea and amide derivatives, preparation and pharmaceutical compositions thereof
TW223630B (en) Retroviral protease inhibitors
MY103241A (en) Imidazole and 1,2,4 triazole derivatives
DK0489877T3 (da) Antiatherosklerotiske og antithrombotiske 2-amino-6-phenyl-4H-pyran-4-oner
AU632846B2 (en) Substituted n-(quinolin-2-yl-methoxy)benzyl-sulphonyl-ureas
SI0861250T1 (en) Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
MY132057A (en) Quinoxalinones, a process for their preparation and their use
MY117934A (en) Process for the preparation of n-methyl-3-(1-methyl-4- piperidinyl)-1h-indole-5-ethanesulphonamide
DK0490816T3 (da) Fluorforbindelser som aromatase-inhibitorer.
GR3023427T3 (en) Heteroarylmethylbenzols aromatase inhibitors
AU6306190A (en) Novel substituted alkyl piperidines and their use as inhibitors of cholesterol synthesis
MX9603348A (es) Derivados de disulfuro de amida indano-2-mercaptoacetilica novedosos utiles como inhibidores de encefalinasa.
NZ504614A (en) Echinocandin derivatives and application as anti-fungal agents
PL313594A1 (en) Triaryl ethylene derivatives for therapeutic applications
TW329388B (en) Intraocular irrigating solution
NO912420L (no) Antiatherosklerotiske og antitrombotiske 1-benzopyran-4-oner og 2-amino-1,3-benzoksazin-4-oner.
PL312966A1 (en) Derivatives of thiocarbamoil

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO PL RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO PL RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1991911326

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2081577

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991911326

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991911326

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载